By Puyaan Singh and Sahil Pandey March 6 (Reuters) - The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate cancer imaging agent, aimed at improving ...

The Reverend Richard Andrew, president of the Methodist Conference and chair of the Darlington Methodist District, is urging men to undergo prostate cancer checks after his own diagnosis.

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

Patients in Leicestershire and Rutland now have access to a new state-of-the-art MRI scanner at the Leicester General ...

Can AI match radiologists in prostate MRI diagnosis? The PARADIGM trial will assess AI detection of clinically significant ...

Our immune system is great at fighting many types of cancer, but it struggles to see prostate tumors. While new treatments ...

PYLARIFY TruVu™ (piflufolastat F 18) injection (also known as 18F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and ...

The former 'Entertainment Tonight' co-host revealed in 2015 that he had been diagnosed with a rare form of prostate cancer ...

Radiopharmaceutical developer Telix Pharmaceuticals Ltd (ASX:TLX) is expanding its push into AI-enabled cancer imaging ...

Artificial intelligence has bounded into the mainstream, into personal lives, classroom assignments and work meetings — so it should be no surprise to find it in doctors’ offices and emergency ...

And it costs all of us ...

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater pati ...